CRISPR Therapeutics (NasdaqGM ... respectively. The recent announcement of the COO's resignation was likely a contributing factor to the decline, adding uncertainty around the company's strategic ...

CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and ...

CRISPR Therapeutics (NASDAQ:CRSP) shares snapped six straight sessions of losses on Wednesday, as the stock closed 3% to $34.18. The Switzerland-based biotech company lost about 19% in the preceding ...

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 4,723 calls trading, 2x expected, and implied vol increasing over 3 points to ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Beam Therapeutics said Monday that it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a debilitating lung condition that may affect tens of ...

Beam Therapeutics said Monday that it used a form of CRISPR called base editing to ... only mild to moderate adverse events — a notable announcement, given the setbacks seen in a study of ...